56 Mahendra

OSCE : Tenegliptin : It is a third generation DPP-4 inhibitor used for treatment of type 2 diabetes. MECHANISM OF ACTION of Teneligliptin is to increase incretin levels (GLP-1 and GIP), which inhibit glucagon release, which in turn increases insulin secretion, decreases gastric emptying, and decreases blood glucose levels. In general incretins (glucagon like peptides) are the substances which increase insulin and decrease appetite by decreasing the gastric emptying. DPP4 dipeptidyl peptide-4 is a enzyme which converts this incretins into its metabolites Which is inhibited by teneligliptin and maintain the levels of incretins which cause insulin release and decreasing the blood glucose levels LEARNING POINTS: My learning points about this patient are - The importance taking detailed history from the patient before and after the onset of I'll health and how it affected his daily life routine  -Importance of Mechanism of action of every drug that is prescribed to the patient. -Telling

This is an online E log book to discuss our patient's de-identified health data shared after taking his/her/guardian's signed informed consent.Here we discuss our individual patient's problems through series of inputs from available global online community of experts with an aim to solve those patient's clinical problems with collective current best evidence based inputs.This E log book also reflects my patient-centered online learning portfolio and your valuable inputs on the comment. A 63 year old male patient residence of Marripeda bangla came with Chief Complaints :-  Burning micturition and increased frequency of passage of urine since one month. Fever since 1 month Back pain since 15 days Vomiting Since 3 days History of presenting illness Patient was apparently asymptomatic one month back then he developed burning micturition which was insidious in onset, no aggravating and relieving factors   Complaints of increased frequency of urine approximately 20 times a da